CXCL9 and neoplasm: Within the tumor microenvironment, the formulation ensures controlled release of CXCL9, enhancing CD8+ T cell infiltration, while dBET6 triggers immunogenic cell death and inhibits IFNγ-induced PD-L1 expression to overcome immune evasion.